UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of ~~May~~August, 2021

Commission File Number 333-250990

SAWAI GROUP HOLDINGS Co., Ltd.

(Translation of registrant’s name into English)

5-2-30, Miyahara

Yodogawa-ku, Osaka 532-0003

Japan

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SAWAI GROUP HOLDINGS Co., Ltd. ~~By: /s/ Yoshiki Sakurai Name: Yoshiki Sakurai Title: Executive Officer, Group Chief Financial Officer and General Manager of Group Financial Department~~

~~Date~~By: ~~May~~ ~~19,~~/s/ ~~2021~~Yoshiki Sakurai_____________________

2Name: Yoshiki Sakurai

~~sawai Long-Term~~Title: ~~Vision~~Executive ~~for~~Officer, ~~2030~~Group ~~and~~Chief ~~Medium-Term~~Financial ~~Business~~Officer ~~Plan -FY2021~~and toGeneral ~~FY2023- Sawai~~Manager of Group ~~Joldings~~Financial ~~Co., LTd. May 2021 1~~ Department

~~Addressing social issues through Sawai Pharmaceutical's long-time businesses~~Date: ~~Medical~~August ~~cost-saving impact from Sawai Pharmaceutical products (JPY~~5, bn) 273.4 FY2018 296.7 FY2019 317.6 FY2020 Sawai Pharmaceutical's business model is to creat a growth cycle through realizing healthy lives for patients and reduced medical expenses, contributing to a sustainable society. Sawai Pharmaceuticals also acheives growth through working to resolve social issues under its corporate philosophy, "Always Putting Patients First." 2 2021

~~Always~~Financial ~~Putting~~Summary ~~Healthier~~for ~~Lives~~ First ~~Working~~ toQuarter ~~resolve social issues through Sawai Group Holdings' businesses Realizing a sustainable society through the generics business Contributing to the extension~~ of healthy lifespsans through new business We will strive to contribute to the health of as many people as possible as a healthcare corporate group developing sustainably alongside society, with the generic drugs as our core business. 3 FY2021

~~CONTENTS sawai I Review~~(IFRS) of the Medium-Term Business Plan, "M1 TRUST 2021" II Recognizing the Business Environment III Our Vision for 2030 IV Medium-Term Business Plan, "START 2024" V Initiatives Resoliving Social Issues VI Appendix 4

~~Review~~August of5, ~~the Medium-Term Business Plan M1 TRUST~~ 2021 ~~sawai 5~~

~~sawai Historical~~Company ~~Growth Trajectory~~Name: -Sawai ~~Succesful~~Group ~~upfront~~Holdings ~~investment made in anticipation of policy impact (increasing demand for generic drugs) has acheived steady growth - Acquired USL* in May 2017, making a full-scale entry into the US market Revenue 44~~Co.3 billion yen FY2008 FY 2011 FY2014 187.2 billion yen FY2017 US businesses 33.6 billion yen Japan businesses 153.6 billion yen FY2020 Acquired US-based USL* in May 2017 Operating Income/Core Operating Income 4.7 billion yen FY2008 FY2011 FY2014 FY2017 34 billion yen 18.9 billion yen FY2020 Acquired US-based USL* May2017 *USL:Upsher-Smith Laboratories, ~~LLC (Note) IFRS standards applied as of FY2018 6~~ Ltd.

~~sawai Review~~Stock ofCode M1Number ~~TRUST 2021 Matters Acheived~~ (Japan): business - Ranked No. 1 and No. 2 in generics in new product sales share - Improve production efficiency by consolidating manufacturing sites through plant transfers, etc. - Launch of single-market and competitive-superior new products - Develop propreitary technologies US business - Expansion of pipelines and product lineups - Started construction of a new factory to strengthen manufacturing capacity via factory consolidation Future Issues Japan business - To further expand market share US business - To realize growth in US business 7 4887

~~sawai Review~~Listed ofStock M1Exchange: ~~TRUST~~Tokyo ~~2021 -~~Stock Despite the severe business environment, both revenue and core operating income increased by 10% during the previous medium-term business plan - Generics volume share in Japan rose 0.8 points to 15.7% Revenue Core operating income (billions of yen) FY2017 FY2020 168.1 187.2 14.9% 15.7% 31.1 34 22.2 18.9 8 Exchange

~~Recognizing~~URL: ~~the Business Environment sawai 9~~ https://www.sawaigroup.holdings

~~sawai Changes in the External Environment~~Representative: ~~Trends~~ ~~and~~Kazuhiko ~~Technologies Changes in Trends A more aging society~~Sueyoshi, ~~changes in values for prevention/pre-symptomatic illness~~President ~~Era of 100-year lifespans Emphasis on prevention of disease~~ and ~~pre-symptomatic~~Representative illness state Increasing medical costs Increasing home care Evolution of Technology Advances in technological innovations such as new modalities, AI, and robots New modalities AI Digital Robotics 10 Director

~~sawai Changes~~Contact ~~in the External Environment~~Person: ~~Overall~~ ~~Outlook~~Yoshiki ~~for~~Sakurai, ~~the~~Executive ~~Japanese Generics Market~~officer ~~Generics~~and ~~volume~~Group share*Chief inFinancial ~~Japan 2017~~Officer ~~2020~~ Tel: ~~70% 79%~~ +81- ~~Generic drugs volume share has reached almost 80% for the three years since 2017~~ 6- Although growth is expected to slow down in the future, the demand is expected to grow to some extent Potential for accelerating industry reorganization due to falling drug prices driving deteriorating profitability *Volume shares are Sawai estimates 11 6105-5818

~~sawai Changes~~Filing inDate ~~the External Environment: Current Situation~~ of ~~the~~Quarterly US Generics Market - US Generics market grew negatively in 2017 and 2018 - The lastest figures have remained almost flat Originator medicine market Branded generics* Generics 6% 0% 2% -4% 0% 2016 2017 2018 2019 2020 *ADNA-approved branded generic drugs SourceReport: ~~IQVIA, national Sales Perspectivies, Novemer 2020 Note~~: ~~Limited~~August ~~to Rx and OTC insulins; Includes Retail~~5, ~~Non-Retail and Mail~~ 12 2021

~~Our~~Scheduled ~~Vision~~Date ~~for~~of ~~2030~~Dividends Payment commencement: ~~sawai 13~~ N/A

~~Sawai~~Supplemental ~~Group~~Materials ~~Vision~~for ~~2030 The~~the ~~World~~financial ~~We Want to Build~~results: A world where more people can receive healthcare services and live a full life with peace of mind among society + Our Ideal State A company with a strong presence that continues to contribute to people's health by providing a multifaceted mix of products and srvices based on scientific evidence that meets individual needs 14 Yes

~~sawai Sawai~~IR ~~Group~~Conference ~~Vision~~on ~~2030: Business Development Fostering new businesses with generics as our core business Providing a wide-range of options, not limited to drug treatment, from prevention to treatment in~~ the ~~primary~~financial ~~care~~Results: ~~field~~Scheduled ~~Entering~~(for ~~the~~institutional ~~new~~investors ~~drug~~and development business in the orphan diseases field in order to provide unprecedented treatment opportunities Sawai Group Holdings Disease Prevention Diagnosis Treatment Generic business Primary care field New businesses Health food business Digital medical devices business Orphan drug development Specialty 15 analysts)

sawai Sawai Group Vision 2030: Quantitative Targets New business U.S. business Japan business Domestic GE share 14.9% 15.7% 20.0% or more 168.1% 187.2 400 billion yen 333 336 New businesses 80 US businesses 60 1,347 1,536 Japan business 260 FY2017 FY2020 FY2023 FY2030 Target (~~Yen/$=100) Targets~~Amount ~~and~~are ~~Prerequisite~~rounded ~~Values As~~to ofthe ~~FY2020 FY2030~~nearest ~~under~~million ~~vision 2030 Japan Business Revenue 153.6 billion~~ yen 260 billion yen Sales volume 13.1 billion tablets 260 billion tablets Share of sales 15.7% 20.0% or more Production capacity 15.5 billion tablets 23 billion tablets or more New businesses Revenue - 80 billion yen US businesses Revenue 33.6 billion yen 60 billion yen Total revenue 187.2 billion yen 400 billion yen ROE 5.8% 10% or more 16 )

~~Medium~~1. Financial Highlights for the First Quarter of FY2021(for the three-~~Term~~month ~~Business~~period ~~Plan,~~ended ~~START~~June ~~2024 sawai 17~~ 30, 2021)

sawai Three Categories for Growth 2024 Onword Generic business 1) Expanding share in the Japanese generics market - Increasing sales of new products - Strengthening stable supply capabilites 2) Business investment for future growth in the US x Entry into new businesses 3) Cultivating new growth areas - Digital medical devices business - Orphan drug business (ALS, etc.) - Health food business 18

(1） Consolidated Operating Results

(% of changes over the same period of the previous year)

Revenue

Operating profit

Profit before tax

Profit for the year

Profit attributable to owners of the Company

Million yen

％

Million yen

％

Million yen

％

Million yen

％

Million yen

％

Three-month Period Ended
June 30, 2021

50,486

－

8,483

－

8,433

－

6,380

－

6,307

－

Three-month Period Ended
June 30, 2020

－

Note: Comprehensive Income:

Three-month Period Ended　June 30, 2021:　 6,174 million <( - %)>

Three-month Period Ended　June 30, 2020:- million <( - %>)

Basic earnings per share

Diluted earnings per share

Yen

Three-month Period Ended
June 30, 2021

144.03

143.93

Three-month Period Ended
June 30, 2020

－

Note: Comparative information is not disclosed since the company was established on April 1, 2021 through a sole-share transfer.

~~sawai~~ (12) ~~Expanding~~Consolidated ~~Generics~~Financial Market Share in Japan: Increasing Sales of New Products Launched 89 prodcuts in three years Strongly competitive products (including single-market products) serve as core drivers for sales Revenue from products launched in the past three years Products launched in FY2018 Products launched in FY2019 Products launched in FY2020 (Unit millions of yen) 13,964 551 1,890 5526 7918 6,514 FY2018 FY2019 FY2020 Numbers of products launched in the past three years and strongly competitive products FY2018 FY2019 FY2020 Number of products 33 14 42 Single-market and strongly 3 7 9 competitive products (included in above) Major products released Capecitabine Micafungin sodium (for IV infusion) Eladecalcitol (generic name) Oseltamivir Tadalafil CI Bazedoxifene Aprepitant Fexofenadine hydrochloride Hydrochloride psuedoephedrine (Pusofeki combination tablets) Repaglinide Varenafil 19 Position

(1) Expanding Generics Market Share in Japand: Increasing sales of New Products Planning for launch of over 85 products in the next three years Going forward, we will continue to outperform inductry peers through our strategy of leveraging our intellectual property strengths and aiming to expand profits in the generics business in Japan as a whole New prodcut launch plan FY2021 FY2022 FY2023 Number of ingredients 14 11 14 Number of products 32 27 26 Original drug market 250.7 288.0 274.4 (billions of yen) Original drugs for first-listed Generic drugs Cymbalta capsule/ Patanol ophthalmic solution/ Samsca OD tablets/ Nexium capsules/ Azilva tablets Also planning launch of single launch products other than those listed above 20

	Total assets	Total equity	Equity attributable to owners of the Company	Ratio of equity attributable to owners of the Company to total assets
	Million yen	Million yen	Million yen	％
As of June 30, 2021	392,471	244,077	221,558	56.5
As of March 31, 2021	－	－	－	－
Note: Comparative information is not disclosed since the company was established on April 1, 2021 through a sole-share transfer.

sawai (1) Expanding Generics Market Share in Japan : Strengthening Stable Supply Capabilities Aiming to further improve supply capacity by taking all reasonable measures in anticipation of industry reorganization and consolidation, e2.~~g.,~~ ~~building~~Cash new factories, acquiring factories, and securing high-quality production contractors Industry-leading production capacity, sales volume Aiming to establish an in-house production system for more than 20 billion tablets Production capacity Sales volume (billions of tablets) 10 15.5 8 13.3 FY2014 FY2020 21 Dividends

sawai Generics Business Foundations in Japan Aiming to further expand share in the Japanese generics market by leveraging Sawai Pharmaceuticals's strengths Sales Human Resources base Manufacturing Financial base RandD Organizational capability Quality management 22

	Dividends per share
	End of first quarter	End of second quarter	End of third quarter	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
For the Fiscal Year Ended June 30, 2021	－	－	－	－	－
For the Fiscal Year Ended June 30, 2020	－
Notes: Revision to the cash dividend estimates since the latest announcement : No

~~sawai Generics Business Foundations in Japan~~Note: ~~Sales~~ ~~Capability Building~~Comparative the Sawai brand through a steady track record of activities Strong trust relationships with wholesalers and distributors Information gathering capability - Information provision system that promptly and accurately conveys product information ~~for approximately 800 items~~ -is ~~Abundant~~not ~~materials~~disclosed ~~and~~since ~~content~~the ~~for~~company ~~patients~~was ~~and~~established ~~medical~~on ~~professionals -~~April ~~Information gathering structure for side effects and safety~~1, ~~designes~~2021 ~~to further improve products - Responding to demand changes~~ through ~~cross-division~~a ~~cooperation Information provision capability Cross~~sole-~~division~~share ~~cooperation 23~~ transfer.

~~sawai Generics~~Additional Business Foundations in Japan : RandD Capability Achieving first new peoduct launch through RandD and drug formulation development capabilities Candidate product survey/analysis Early start of RandD - Track record of approvals of around 800 items - Abundant experience in patent invalidation trials, oatent infringement proceedings, etc. - Close collaboration with external experts, including intellectual property lawyers - Personnel structure for acheiving a wide range of first launches - Developing proprietary technologies Expanding pipelines Drug development capability 24 Information

~~sawai Generics~~(1) ~~Business~~Material Foundations in Japan: Stable Supply Capability Acheiving stable supply by making full use of expertise as a generics-dedicated manufacturer and internal and external production capabilities Purchasing power - Procurement structure capable of rapidly responding to fluctuating demand for raw materials - Promoting multi-source purchasing from multiple suppliers - Capability for discovering new suppliers - Delivery adjustment capability - Price negotiation capability Manufacturing skills - Manufacturing skills capable of high-mix, large-lot production - Stratified personnel development for enhancing on-site capabilities - Promotion of skill versatility education Cross-division cooperation - Responding to demand changes ~~through cross-division cooperation - Technological capabilities for steady shift to commercialization~~ in asubsidiaries ~~short~~during this period: of time - Rapidly responding to quality issues through GQP compliance and cooperation with Quality Assurance team at factories Inventory holding capacity - Ensuring proper inventories - Capability to felxibly adjust production plans 25N/A

~~sawai Generics~~(2) ~~Business~~Changes ~~Foundations~~ in ~~Japan~~accounting ~~: Quality~~policies Management System Implementing a variety of intiatives to provide a higher standard of quality Management of API manufacturing sites - Approximately 100 of around 450 API manufacturing plants are audited annually, including written and ~~on-site~~accounting ~~audits -~~estimates ~~Plan~~(i) toChanges ~~conduct 240 audits~~ in ~~the~~accounting ~~next~~policies ~~three~~required ~~years to FY2023 - Drawing up a multilingual manual and standardizing audit details Management of drug manufacturing sites - In accordance with GQP*, products manufactured~~ by ~~our~~IFRS: ~~factories~~N/A ~~and~~(ii) ~~factories~~Changes contracted are audit to conform to the approvl standarts of the Minitry of Health, Labour and Welfare, and provide quality improvement guidance as necessary - Compliance with GMP** standards from the Minstry of Health, Labour and Welfare in ~~factory~~accounting ~~processes Post-shipment~~policies ~~quality~~other ~~management -~~than Single-lot samplings each year for all 800 products based on PIC/S, conducting long-term stability tests Pharmaceutical affairs correspondence - Compliance with ICH Q3D and PIC/S - COmpliance with revisions of the PMD Act * GQP (~~Good Quality Practice~~i): ~~Criteria for checking whether the company's manufacturing factory or contracted manufacturer is conducting proper manufacturing control~~N/~~quality~~A ~~control **GMP~~ (~~Good Manufacturing Practice~~iii): ~~Standards~~Changes ~~for~~in ~~pharmaceutical~~accounting ~~manufacturing~~estimates: ~~cotrol and quality control by the Ministry of Health, Labour and Welfare 26~~ N/A

~~sawai~~ (23) ~~Business~~Number ~~investment for future growth in the US business Future earnings image 60 billion yen Launch~~ of ~~paragraph~~shares IVissued ~~products 33.6 yen FY2020 FY2023 (Yen/$=100) START 2024 FY2030 t Sawai Group Vision 2030 Planning upfront investment in facilities~~ and ~~RandD,~~outstanding ~~etc.~~(common ~~for improving profitability in the future during the three-year period ending in FY2023 Aiming for growth from 2024 onward 27~~ stock)

~~sawai Strategy and Growth Drivers for US Business~~ (~~USL~~i) ~~Desired~~ ~~State Upsher-Smith~~Number ~~will~~of ~~drive~~shares ~~sustainable long-term growth as a specialty generic company focused on generics~~ issued and ~~small~~outstanding ~~brands~~(including ~~that~~treasury ~~leverage~~stock) ~~its~~at ~~unique~~the ~~commercial~~end ~~capabilities Growth Driver Contribute to sales by promoting sales~~ of ~~existing~~each ~~brand drugs and generics Further expansion of product lineup mainly in niche generics Strengthen product pipeline with high complexity and product lineup in cooperation with Sawai Pharmaceutical 28~~ period:

~~sawai Outline~~ June ~~of Strategies for US Operations (USL) Products Strategy Existing Products Focus on key products - Zembrace~~30, ~~Tosymra~~2021: ~~Utilize specialty pharmacy~~43, ~~reduce the use of Platinum Pass to improve ASP~~791,339 actively visit doctors, and undertake other measures to expand sales channels - Vigadrone: Aim to increase the revenue - Qudexy: Aim to retain sales of Topiramate, which is the authorized generic of Qudexy, utilizing specialty pharmacy New products pipeline Generic Drugs Currently 42 development pipeline items with a total market size of $4.5 billion Subsequent addition of pipeline with focus on niche generics 505(b)(2) Developing corticotropin injection, a drug for infantile spasms, multiple sclerosis, and other indications, in collaboration with AmbioPharm Pre-IND meeting with FDA for product development scheduled in May Paragraph IV Aim to sell pitavastatin tablets and mirabegron tablets in the US in the future Additions to Paragraph IV products Orphan drugs Sawai Pharmaceutical, in cooperation with Neugen Pharma, is developing a drug amyotrophic lateral sclerosis (ALS). Launch the clinical study in the US in 2021 Cost control measures Capital Expenditures to improve prodcution efficiency Review overall costs 29 shares

~~sawai US~~ March ~~business~~31, 2021: N/A (~~USL~~ii)~~: Planned~~ ~~launches~~Number of ~~generic~~treasury ~~drugs Planning~~stock ~~for~~at ~~launches of over 30 products in~~ the ~~next~~end ~~three years Total market size for these product is approximately 430 billion yen Expected number~~ of ~~generic~~each ~~drugs launch in the next 3 years 5 9 16 1 1 5 1 5 9 3 3 2 FY2021 FY2022 FY2023 Low Complexity Medium Complexity High Complexity 30~~ period:

~~sawai Project~~ March to31, create a new factory in the US business (USL) Overview - Consolidating all marketed products into a single manufacturing plant - Consolidation to a single manufacturing plant to lower operating expenses and improve qualiy and efficiency - Planned total investment amount for the construction and Denver product transfer2021: ~~$13 billion yen~~ ~~Expected~~237 benefit 1. Expected annual manufacturing cost reduction of approx. 1 billion yen from 2023 onward through consolidation of facilities and repatriation of CMO products 2. Improved efficiencies driven by the long-term benefit of consolidating operations into modernized facility 3. Improved quality through electronic batch records, better material and manufacturing flow and improved equipment Key Milestones Jul 2022 Qualification and Validation complete Dec 2022 Denver product transfer complete 31 shares

~~sawai (3)~~ March ~~Cultivating~~31, ~~New Growth Areas~~2021: ~~Entry Into New Businesses~~ ~~- Focusing resources on three areas: new drug businesses~~ N/A (~~orphan diseases~~iii), ~~Digital~~Average ~~medical~~number ~~devices~~of ~~business,~~shares issued and ~~Health~~outstanding ~~food business - In addition to investing~~ in ~~existing~~each ~~businesses, setting an investment budget of 30 million yen in new business areas during the~~ period of the Medium-Term Business Plan Specialty Drugs New drug businesses Orphan dieases (e.g., ALS) Primary Care Digital medical devices business Depression/psychosis treatment Diabetes/lifestyle-related disease management Health food business Pre-symptomatic illness measures Longer healthy lifespans 32 :

~~sawai (3)~~ Three-month ~~Cultivating New Growth Areas: New Businesses: Orphan Diseases~~period ~~ALS~~ended treament WN1316/SW007 Jointly develop WN1316, a drug for amyotrophic lateral sclerosis (ALS) treatment, which was discover by Neugen Pharma, targeting global markets including North America, Europe, Asia, and Japan, for all indications applicable as an ethical drug.(announced in June ~~2020) Advance the devlopment of optimixing each company's expertise - Neugen Pharma's knowledge on ALS and Sawai's clinical RandD capability including drug development Target markets~~30, ~~numbers of ALS patients The United States is the main target market for the time being Between around 20~~2021:43,~~000 to 30~~791,~~000~~142 ALS patients in the US Future plans To launch Phase I clinical studies in the US after FY2021 Market launch target: 2025 or thereafter Aiming to expand the pipeline targeting orphan diseases in the future 33 shares,

~~sawai (3)~~ Three-month ~~Cultivating New Growth Areas: New Businesses: Digital Medical Devices Business~~period ~~(Central~~ended ~~Nervous~~June ~~System area) Aiming to be the only player in the industry who can provide a trifecta solution In the central nervous system area~~30, recent years have seen increasing needs for device therapy and cognitive behavorial therapy in addition to drug therapy. On the other hand, the development and provisoin of solutions are still limites. Generic Drugs Product lineup in central nervous system area2020: 46 generals with 144 strengths Digital therapuetics Neuromodulation In addition to drug treatment with generic drugs, we are aiming to provide services utilixing cognitive behavorial therapy applications (DTx) and neuromodulation 34 N/A

~~sawai (3) Cultivating New Growth Areas~~Note: ~~New~~Comparative ~~Businesses~~information ~~- Digital Medical Devices Business~~is ~~Capital~~not ~~and~~disclosed ~~business~~since ~~alliance with SUSMED Through~~ the ~~investment in SUSMED, a digital therapeutic~~ company ~~with~~was ~~applications~~established ~~for~~on ~~treating~~April ~~insomnia~~1, ~~collaborations~~2021 that can blend and optimize SUSMED's technology and knowledge in the digital healthcare field and Sawai Pharmaceutial's generic business are under consideration (announced September 2020) Looking ahead We continuously consider improving operational efficiency, such as reduction of RandD costs using SUSMED's blockchain technology, and collaboration in the areas of deperession and psychiatry Medical devices for migraines/depression We have entered into an exclusive development and marketing agreement with Neurolief, targeting the Japanese market. Neurolief's non-invasive nueromodulation device allows patients to use it at home, and can share treatment data with their physician, in addition to uploading the data to the cloud database through a ~~dedicated app. It is also designed to self~~sole-~~learn~~share ~~and analyze the treatments using AI technology in order to optimize the treatments for patients according to their symptoms~~transfer.(announced January 2021) Proposed as new treatment method to patients who are receiving drug treatment but feel no effect. Number of target patients 392,000 (Patients with migraines who are non-responsive to drug treatment) 174,000 (Patients with acute depression who are non-responsive to drug treatment) Future plans For migraine- Application: 2022, Launch target: 2023 For depression - Application: 2023, Launch target: 2024 35

~~sawai (3)~~This ~~Cultivating~~financial ~~New~~summary ~~Growth~~is ~~Areas: New Businesses - Digital Medical Device Business Contributing to improving people's lifestyles, health and quality of life by providing and utilizing medical and health information,~~ not ~~only~~subject ~~pharmaceuticals Patients Physicians Pharmacist Sawai Group Holdings Corporate health insurers Municipalities Through strategic alliances with various companies, we broadly contribute~~ to ~~medical~~audit ~~care~~ by ~~providing~~certified ~~solutions~~public ~~that~~accountants ~~utilize~~or ITaudit technologies - Support from prevention to treatment for lifestyle-related diseases and chronic diseases using PHR* data - Support for addressing diversifying medical treatment styles - Support for health activities of companies and local governments - Support for regional medical cooperation Aiming to play a role in connecting various stakeholders, efirms.~~g., patients and medical professionals *PHR (Personal Health Record) is a mechanicsm for patients to collect and centrally store their own medical/health information 36~~

~~sawai (3)~~Cautionary ~~Cultivating~~Statement New Growth Areas: New Businesses - Health Food Business - Considering entry into the health food business, where we would support longer healthy lifespans in the areas of pre-symptomatic illness and prevention (e.g., locomotive syndrome/fraility measures, and dementia/lifestyle-related disease prevention) Test Results Good Bad Symptoms No Health Pre-symptomatic illness Yes Pre-symptomatic illness Sawai Illness Target Markets 2.3 trillion yen scale of total health food market The market for extending healthy lifespands, including a number of areas such as locomotive syndrome/fraility/dementia covers 18% of the market In addition, the market covers many people receiving insurable medical treatment Future Plans We plan to proceed with aRespect ~~balanced exploration, including whether~~ to ~~proceed in~~Forward-~~house~~Looking orStatements, ~~in partnership with other companies Searching for development centered on the intermediate value theme of medical care~~ and ~~health 37~~ Other Information

~~sawai Investment~~The ~~Plan and Shareholder Returns Investment Plan and Expected Shareholder Returns in the Medium~~year-~~Term~~end ~~Business~~earnings ~~Plan~~conference ~~Period RandD~~for ~~expenses Approx. 45 billion yen~~institutional ~~(Generic~~investors ~~drug~~and ~~business) For~~analysts ~~expanding~~is ~~product lineup,~~scheduled ~~investing approx.~~on 75August ~~billion yen cash total Expected generics business RandD investment/ operating cash flow over acquisitions three years: Approx. 100 billion yen (e.g.~~5, ~~products) Approx~~2021. 30Presentation ~~billion yen Capital investment Approx. 70 billion yen (Japan: Approx. 60 billion yen, USA: Approx. 10 billion yen) Cash~~ and ~~deposits approx.~~related 54materials billion yen New Businesses 30 billion yen (FY 2021) (planned investment amount) Shareholder returns 17 billion yen or more in total dividends over three years (conducting consistent, ongoing dividends with target of ~~130 yen/share~~the ~~annually~~conference ~~and~~will ~~payout ratio~~be ofpromptly ~~30%) + Financing~~posted ~~capabilites with~~on ~~RandI~~our ~~rating of A- 38~~ website.

~~Intiatives~~Attachment ~~Resolivng Social Issues sawai 39~~Index

sawai Intiatives Resolving Social Issues Issues to address Targets (quantitative/etc.) Main businesses 1) Contributing to sustainable social Achieving medical cost savings impact of approx security systems and improved access 2x of Japan and US generics business sales to healthcare (medical cost savings using generics) 2) Contributing to longer healthy lifespans Expanding business to a wider range of healthcare through new businessess domains, including pre-sympyomatic illness and prevention Relationships with stakeholders 3) E: Environmentally friendly production Cuts of 25% in CO2 emissions on production volume insensity basis (FY2030) Waste plastic recycling rate of 65% or more (in 2030) 4) S: Talent development, work styles/ Safe and diverse work environment motivation, respect for human rights Promotion of diversity Initiatives for respect of human rights 5) G: Deepening corporate governance Improvement and deepening of governance through conversion to holding company structure Stronger risk management/compliance 40

1.		Financial Highlights for the Three-month Period Ended June 30, 2021	2
	(1)	Operating Results	2
	(2)	Financial Position	5
	(3)	Cash Flow	5
2		Condensed Quarterly Consolidated Financial Statements and Selected Notes	6
	(1)	Condensed Quarterly Consolidated Statements of Income and Condensed Quarterly Consolidated Statement of Comprehensive Income	7
	(2)	Condensed Quarterly Consolidated Statements of Financial Position	8
	(3)	Condensed Quarterly Consolidated statements of Changes in Equity	10
	(4)	Condensed Quarterly Consolidated Statements of Cash Flows	11
	(5)	Selected Notes to Condensed Quarterly Consolidated Financial Statements	12
		(Significant Uncertainty Regarding Going Concern Assumption）	12
		(Key Accounting Policies）	12
		(Segment Information)	12

~~sawai Post~~-~~COVID-19: Proactively Addressing Efficient, Diverse Work Styles Clean slate review of traditional ways of doing business Acheiving efficiency gains worth over~~ 1 ~~billion yen in the Medium~~-Term Business Plan period by improving operations Operational improvements post-COVID-19 Issues faced in realizing diverse work styles Permanent remote work system Review of work systems Reviewing of physical space (e.g., offices) Going paperless Proactively leveraging digital technologies 41

~~Caution Regarding Future Outlooks~~1．Financial ~~The~~Highlights ~~information~~for ~~in this document is based on a variety of assumption, and do not constitute a guarantee or promise of~~ the ~~execution~~Three-month ofPeriod ~~measures~~Ended orJune ~~future planning or target figures described. Contact Sawai Group Holdings Co.~~30, ~~Ltd. Group Public Relations / IR Office Email: ir@sawai.co.jp 42~~ 2021

Sawai Group Holdings Co., Ltd. (the “Company”) was established on April 1, 2021 through a sole-share transfer from Sawai Pharmaceutical Co., Ltd. Because it was a transaction under common control, there is no substantial change in the scope of the consolidated financial statements. Accordingly, the Company prepares the condensed quarterly consolidated financial statements for the three-month period ended June 30, 2021 with the comparative information being derived from the condensed quarterly consolidated financial statements of Sawai Pharmaceutical Co., Ltd. for the three-month period ended June 30, 2020 and the consolidated financial position of Sawai Pharmaceutical Co., Ltd. as of March 31, 2021.

(1) Operating Results

The Company and subsidiaries (collectively, “Sawai”) has adopted International Financial Reporting Standards (“IFRSs”) since the year ended March 31, 2018, in order to increase the international comparability of its financial information within the capital market.

During the three-month period ended June 30, 2021, revenue increased to JPY 50,486 million (by 14.9%), operating profit increased to JPY 8,483 million (by 23.3%), profit before tax increased to JPY 8,433 million (by 23.8%), and profit attributable to owners of the Company increased to JPY 6,307 million (by 15.3%) compared to the three-month period ended June 30, 2020.

(Millions of yen, except percentages)
	Three-month period ended June 30, 2020	Three-month period ended June 30, 2021	Change	Change (%)
Revenue	43,942	50,486	6,544	14.9
Operating profit	6,881	8,483	1,602	23.3
Profit before tax	6,814	8,433	1,619	23.8
Profit attributable to owners of the Company	5,470	6,307	837	15.3

In May 2021, Sawai announced its long-term vision, “Sawai Group Vision 2030,” and its medium-term business plan, “START 2024,” which contains the operating plan through the fiscal year ending March 2024. “Sawai Group Vison 2030” defines the corporate image to be achieved by 2030 as: “The world we want to build: A world where more people receive healthcare services and live a full life with peace of mind among society”; and “Our ideal state: A company with a strong presence that continues to contribute to people’s health by providing a multifaced mix of products and services based on scientific evidence that meets individual needs.” Additionally, our long-term vision identifies the “expansion of shares in the Japanese generics market”, “business investment for future growth in the US”, and “cultivation of new growth areas” as the plan’s three core targets. As per START 2024, Sawai will increase sales of new products and strengthen stable supply capabilities in the generics sector along with increasing investments in new sectors specifically the digital medical devices, orphan drugs (ALC, etc.), and health food businesses.

(i) Japan Business Segment

In the Japan Business segment, the Cabinet approved the “Basic Policy for Economic and Fiscal Management and Reform 2017: Improving Productivity Through Investment in Human Resources,” in June 2017, which seeks to realize the 80% use of generic drugs by September 2020. To achieve this goal, the Cabinet approved the “Basic Policy on Economic and Fiscal Management and Reform 2019 – A New Era of Reiwa: Challenges toward Society 5.0” (Basic Policy 2019) in June 2019, which states that: “With regard to the promotion of the use of generic drugs, while ensuring stable supply and greater reliability of quality, the government will continue to strive to realize the 80 percent use of generic drugs by September 2020, strengthening incentives.” Moreover, to promote the use of generic drugs, the April 2020 revisions introduced measures to further incentivize pharmacies and medical institutions to dispense or prescribe a higher percentage of drugs using the generic names of the active ingredients, as opposed to original drugs which are often called by their brand names. As a result, the share of generic drugs was expanded to as much as 78.3% in September 2020, according to the (preliminary) price list survey conducted by the Japanese government.

-2-

Under such circumstances, there has been supply uncertainty in generic drugs as a whole, as a result of adverse health effects arising from medicines manufactured by a second-tier generic drug company, as well as violations of the “Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices” by a major generic drug company. Therefore, in the “Basic Policy on Economic and Fiscal Management and Reform 2021” (the “Framework Policy”) approved by the Cabinet in June 2021, the new goals for generic drugs were set to ensure the quality of generic drugs and the reliability of their stable supply with the public and private sectors collaborating to strengthen manufacturing control systems, tighten supervision of manufacturing facilities, and conduct quality verification inspections of products distributed in the market. At the same time, it targeted to increase the volume and share of generic drugs to more than 80 percent in all prefectures by the end of fiscal year ending March 2024.

On the other hand, Sawai has experienced downward pressure on prices at an accelerated rate. This is attributable to the consecutive revisions to the drug pricing list, a one-off decrease in October 2019 associated with an increase in the Japanese consumption tax rate, followed by the consecutive annual revision in April 2020 and April 2021.

Within this environment and under our medium-term business plan titled, “START 2024,” Sawai, as the leading generic company in Japan, is working to reinforce the quality control system, increase sales of new products, and strengthen our capability to provide a stable supply in order to contribute the restoration of trust in the generic industry as well to achieve our mid-term target of “expansion of shares in the Japanese generics market”.

In terms of quality control, although there have been critical Good Manufacturing Practice (GMP) violations by certain companies in the generic drug industry, we, as the leader in this industry, have minimized quality-related risks by taking measures such as ensuring the quality of Active Pharmaceutical Ingredients (APIs) in compliance with GMP, implementing a quality control system through ongoing confirmation of GMP compliance at manufacturing facilities, and adopting manufacturing and quality control measures based on the Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme (PIC/S-GMP), a non-binding, informal co-operative arrangement between Regulatory Authorities in the field of GMP of medicinal products for human or veterinary use. Furthermore, to ensure that medical professionals are able to use our products comfortably, we disclosed the names of all the manufacturing subcontractors and active pharmaceutical ingredient suppliers and dates of audit performed over their operations as well as released a video introducing Sawai’s efforts to improve quality control in June 2021.

In terms of our production and supply systems, we are pursuing even higher efficiency and lower costs to further accommodate growing demand and declining supply for generic drugs through utilizing the unique characteristics of each of the six factories scattered across Japan.

In terms of product development and marketing, we launched 8 generic drugs with 23 strengths, including “Eszopiclone tablets,” in June 2021.

Furthermore, we began collaborating with Integrity Healthcare Co., Ltd. in the field of personal health records (PHR) from May 2021, as PHR has become more important with the rapid growth and spread of online medical consultations. From now, Sawai will sell the “Smart One Health,” a PHR management system that Integrity Healthcare developed under the Sawai brand, making Integrity Healthcare an OEM. Also, as a service that contributes to the prevention and treatment of chronic diseases, primarily lifestyle-related diseases, we plan to provide various solutions for medical institutions, companies, health insurance unions, and local governments through the management and sharing of PHR data.

For our COVID-19 countermeasures, we have established a Crisis Management Office based on the Rules on Crisis Management and the Disaster BCP in February 2020 and have taken steps to prevent infection by strengthening internal office ventilation and disinfection and ensuring that employees maintain hand hygiene, wear masks, and undertake temperature screenings. We also have mandated web-based meetings and revised internal rules regarding long-distance business trips, as well as modifying work policies to accommodate to flex time, staggering work hours, and implementing work-from-home, while continuing to operate each plant in Japan and to ensure a stable supply of products. Under the Government of Japan’s state of emergency, our medical representatives (MR) have refrained from visiting medical institutions and shifted to utilize digital technology to provide services. If the impacts of the pandemic were to be prolonged, among other things, it is expected to affect the supply of pharmaceuticals due to stagnation of raw material imports and logistics, the demand for pharmaceuticals due to the restraints on patient consultations, and the restrictions on sharing pharmaceutical information. As a company primarily manufacturing and selling pharmaceuticals, we continue to adopt measures that prevent infections and maintain a stable supply of pharmaceuticals, which are essential to people’s lives and health.

-3-

As a result, the segment reported net sales of JPY 43,487 million (23.7% increase compared to the same period of the previous year), and segment profit of JPY 8,091 million (23.6% increase compared to the same period of the previous year).

(ii) U.S. Business Segment

We have entered the U.S. market by acquiring Upsher-Smith Laboratories, LLC (USL) in May 2017. As per the medium-term business plan, “START 2024,” Sawai will make investments towards our future growth in the U.S business segment with “contribution to sales by promoting sales of existing brand drugs and generics”, “further expansion of product lineup mainly in niche generics”, and “strengthening of product pipeline with high complexity and product lineup in cooperation with Sawai Pharmaceutical” as growth drivers. To accelerate our growth strategy in the U.S. Business segment, we will be working closely with Sumitomo Corporation of the Americas, a U.S. subsidiary of Sumitomo Corporation who owns a 20% interest in USL.

In the U.S. generic drug market, generic drug prices constantly declined although there were some signs of recovery observed recently. These events are plausibly the result of the three major purchasing groups holding approximately 90% of the market share, with the formation of alliances amongst wholesalers and pharmacies, and also the high number of approvals for Abbreviated New Drug Applications (ANDA) by the U.S. Food and Drug Administration (FDA). For USL, the COVID-19 pandemic’s negative impact, which has been affecting the sales of Tosymra, acquired in 2019, have lessened, and the quantities of sales of Tosymra are showing signs of recovery. However, the business environment remains challenging from increasing competition in the generic market, as seen in the introduction of generics to our core branded product, Qudexy.

Given the surrounding environment, we expanded our product offerings by launching two generic drugs, “Moxifloxacin Ophthalmic Solution” and “Isotretinoin Capsules,” released in May 2021 and June 2021, respectively.

In April 2021, USL sold and leased back its factory in Denver, Colorado, intending to gradually transfer its manufacturing operation to the newly built factory at USL’s headquarter in Minnesota, in order to improve quality control and production efficiency.

In early March 2020, USL established, COVID-19 Response Team, a cross-departmental response team, to gather a wide-range of information and develop countermeasures. Apart from certain employees who are essential for on-site operations such as those in manufacturing and R&D departments, USL transitioned to telework, implemented measures to prevent the spread of infection among employees, introduced other human resource measures, and switched to technology-based sales activities. However, vaccination of the Covid-19 vaccines have been progressing steadily in the U.S., and economic activities are on the verge of returning at the normal level. Although the pandemic has discouraged patients from seeking medical assistance and restricted business activities, USL continues to adopt measures that prevent infection and maintain a stable supply system for the pharmaceutical products, which are essential to maintaining people’s life and health.

As a result, the segment reported net sales of JPY 6,999 million (20.3% decrease compared to the same period of the previous year) and segment profit of JPY 392 million (17.7% increase compared to the same period of the previous year).

-4-

(2) Financial Position

Assets

As of June 30, 2021, current assets amounted to JPY 205,334 million, a decrease of JPY 340 million from March 31, 2021, that was primarily due to a decrease in trade and other receivables (JPY 4,441 million) and an increase of cash and cash equivalents (JPY 3,504 million). Non-current assets as of June 31, 2021 was JPY 187,137 million, a decrease of JPY 530 million from March 31, 2021, primarily due to an increase of property, plant and equipment (JPY 1,104 million), offset by an amortization of intangible assets (JPY 1,467 million). Total assets as of June 30, 2021 was JPY 392,471 million, a decrease of JPY 870 million compared to the balance as of March 31, 2021.

Liabilities

As June 30, 2021, current liabilities amounted to JPY 87,295 million, an increase of JPY 6,843 million from March 31, 2021. The increase was due to decrease in trade and other payables (JPY 2,748 million) and increase in bonds and borrowings (JPY 11,414 million) mainly as a result of reclassification from non-current liabilities of bonds that are to be matured on June 2022. Non-current liabilities as of June 30, 2021 was JPY 61,099 million, a decrease of JPY 11,040 million from March 31, 2021, primarily due to the reclassification of bonds to current liabilities described above and other factors leading to a JPY 10,770 million decrease in bonds and borrowings. Total liabilities as of June 30, 2021, was JPY 148,394 million, a decrease of JPY 4,197 million compared to the balance as of March 31, 2021.

Equity

Total equity as of June 30, 2021 was JPY 244,077 million, an increase of JPY 3,327 million compared to the balance as of March 31, 2021, primarily because of net profit for the three-month period ended June 30, 2021, offset by dividend payments and unfavorable exchange effects. As a result, ratio of equity attributable to owners of the Company to total assets as of June 30, 2021 became 56.5% (55.5% as of March 31, 2021).

(3) Cash Flow

Cash and cash equivalents as of June 30, 2021 increased by JPY 3,504 million to JPY 57,773 million, compared to the balance as of March 31, 2021.

The results of cash flow for each activity are as follows:

Cash flows generated from operating activities was JPY 10,597 million for the current period (increase of JPY 2,940 million compared to the same period of the previous year) which mainly consists of profit before tax (JPY8,433 million), depreciation and amortization (JPY 4,314 million), decrease in trade and other receivables (JPY4,560 million), decrease in trade and other payables (JPY 1,155 million), increase in refund liabilities (JPY 1,192 million)and income taxes paid (JPY 2,961 million).

Cash flows used in investing activities was JPY 4,451 million for the current period (increase of JPY1,121 million compared to the same period of the previous year) which mainly consists of acquisition of property, plant and equipment (JPY 5,089 million), sales of property, plant and equipment (JPY 2,808 million) and acquisition of intangible assets (JPY 1,986 million).

Cash flows used in financing activities was JPY 2,628 million for the current period (decrease of JPY 466 million compared to the same period of the previous year) which mainly consists of payments of dividend (JPY 2,846 million).

-5-

2． Condensed Quarterly Consolidated Financial Statements and Selected Notes

(1) Condensed Quarterly Consolidated Statements of Income and Condensed Quarterly Consolidated Statements of Comprehensive Income

（Condensed Quarterly Consolidated Statements of Income）

	Yen in millions (except per share data)
	Three-month period ended June 30, 2021
Revenue		50,486
Cost of sales		(31,777)
Gross profit		18,709
Selling, general and administrative expenses		(8,106)
Research and development expenses		(4,185)
Other income		2,067
Other expenses		(2)
Operating profit		8,483
Finance income		68
Finance expenses		(118)
Profit before tax		8,433
Income tax expenses		(2,053)
Profit for the period		6,380
Profit attributable to:
Owners of the Company		6,307
Non-controlling interests		73
Total		6,380
Earnings per share (Yen)
Basic earnings per share		144.03
Diluted earnings per share		143.93

-6-

（Condensed Quarterly Consolidated Statements of Comprehensive Income）

	Yen in millions
		Three-month period ended June 30, 2021
Profit for the period		6,380
Other comprehensive income (loss)
Items that will not be reclassified to profit or loss:
Changes in fair value of financial assets measured at fair value through other comprehensive income		(71)
Items that may be reclassified to profit or loss:
Exchange differences on translation of foreign operations		(135)
Other comprehensive income (loss) for the period, net of tax		(206)
Total comprehensive income for the period		6,174
Total comprehensive income attributable to:
Owners of the Company		6,127
Non-controlling interests		47
Total		6,174

-7-

(2) Condensed Quarterly Consolidated Statements of Financial Position

	Yen in millions
		As of June 30, 2021
Assets
Current assets
Cash and cash equivalents		57,773
Trade and other receivables		65,666
Inventories		78,999
Other financial assets		148
Other current assets		2,748
Total current assets		205,334
Non-current assets
Property, plant, and equipment		85,812
Goodwill		39,258
Intangible assets		53,005
Other financial assets		6,306
Other non-current assets		1,076
Deferred tax assets		1,680
Total non-current assets		187,137
Total assets		392,471

-8-

	Yen in millions
		As of June 30, 2021
Liabilities and equity
Liabilities
Current liabilities
Trade and other payables		47,654
Bonds and borrowings		15,248
Income taxes payable		2,182
Refund liabilities		8,729
Provisions		284
Other financial liabilities		6,747
Other current liabilities		6,451
Total current liabilities		87,295
Non-current liabilities
Bonds and borrowings		55,971
Provisions		674
Other financial liabilities		2,938
Other non-current liabilities		1,458
Deferred tax liabilities		58
Total non-current liabilities		61,099
Total liabilities		148,394
Equity
Share capital		10,000
Capital surplus		73,672
Retained earnings		135,890
Treasury shares		(1)
Other component of equity		1,997
Equity attributable to owners of the Company		221,558
Non-controlling interests		22,519
Total equity		244,077
Total liabilities and equity		392,471

-9-

(3) Condensed Quarterly Consolidated statements of Changes in Equity

Three-month period ended June 30, 2021

Yen in millions
	Equity attributable to owners of the Company						Non-controlling interests	Total equity
	Share capital	Capital surplus	Retained earnings	Treasury shares	Other component of equity	Total	Non-controlling interests	Total equity
Balance at April 1, 2021	41,219	42,453	132,429	－	2,177	218,278	22,472	240,750
Profit for the period			6,307			6,307	73	6,380
Other comprehensive income					(180)	(180)	(26)	(206)
Total comprehensive income	－	－	6,307	－	(180)	6,127	47	6,174
Acquisition of treasury shares				(1)		(1)		(1)
Dividends			(2,846)			(2,846)		(2,846)
Transfer	(31,219)	31,219				－		－
Total transactions with owners	(31,219)	31,219	(2,846)	(1)	－	(2,847)	－	(2,847)
Balance at June 30, 2021	10,000	73,672	135,890	(1)	1,997	221,558	22,519	244,077

-10-

(4) Condensed Quarterly Consolidated Statements of Cash Flows

	Yen in millions
		Three-month period ended June 30, 2021
Cash flows from operating activities
Profit before tax		8,433
Depreciation and amortization		4,314
Impairment loss		826
Financial income		(66)
Financial expenses		119
Loss on sale and disposal of property, plant and equipment and intangible assets		(1,989)
Decrease in trade and other receivables		4,560
Decrease in inventories		104
Decrease in trade and other payables		(1,155)
Increase in refund liabilities		1,192
Decrease in provisions		(104)
Increase in other financial liabilities		78
Other		(2,671)
Subtotal		13,641
Interest received		1
Dividends received		65
Interest paid		(149)
Income taxes paid		(2,961)
Cash flows generated from operating activities		10,597
Cash flows from investing activities
Acquisition of property, plant and equipment		(5,089)
Sale of property, plant and equipment		2,808
Acquisition of intangible assets		(1,986)
Other		(184)
Cash flows used in investing activities		(4,451)
Cash flows from financing activities
Net proceeds from short-term borrowings		1,600
Repayments of long-term borrowings		(958)
Payments of lease liabilities		(423)
Dividends paid		(2,846)
Others		(1)
Cash flows used in financing activities		(2,628)
Effect of exchange rate change on cash and cash equivalents		(14)
Net decrease in cash and cash equivalents		3,504
Cash and cash equivalents at beginning of the period		54,269
Cash and cash equivalents at the end of the period		57,773

-11-

(5) Selected Notes to Condensed Quarterly Consolidated Financial Statements

(Significant Uncertainty Regarding Going Concern Assumption）

Not applicable

(Key Accounting Policies）

Sawai’s key accounting policies are the same as the “Key Accounting Policies” stated in the securities report filed by Sawai Pharmaceutical Co., Ltd. on June 28, 2021 except for the application of the newly adopted accounting policy described below. Hence, there are no material changes to the key accounting policies applied during the first quarter. Sawai calculated income tax expenses for the three-month period ended June 30, 2021 based on the estimated average annual effective tax rate.

With respect to the accounting policies for leasing, Sawai newly adopted the following sale-and-leaseback accounting policy for financial statements.

For sale and leaseback transactions, Sawai considers when performance obligations have been satisfied in order to confirm whether the transfer of assets should be accounted for as a sale, and is generally considered as such if legal title is transferred to the buyer-lessor and there is no repurchase option on the asset.

If the transfer of the asset is a sale, Sawai derecognizes the underlying asset and recognizes a right-of-use asset arising from the leaseback at the proportion of the previous carrying amount of the asset that relates to the right of use retained. Any gain or loss that relates to the rights transferred to the buyer-lessor is recognized in profit or loss.

(Segment Information）

Sawai’s operating segments are the components for which separate financial information is available, and the Board of Directors as the chief operating decision maker, regularly assesses the financial information in deciding how to allocate resources, measure performance and forecast future periods. Sawai manufactures and sells generic pharmaceutical products with operations in Japan and the United States, each requires differing marketing strategies. Accordingly, Sawai has designated two operating segments, Japan Business segment, and U.S. Business segment.

Three-month period ended June 30, 2021

		Yen in millions
	Operating segment				Adjustments and elimination	Amount recorded in the condensed quarterly consolidated statements of income
	Japan Business		U.S. Business	Total	Adjustments and elimination
Segment revenue
Revenue from external customers	43,487		6,999	50,486	－	50,486
Intersegment revenue or transfers	－		－	－	－	－
Total	43,487		6,999	50,486	－	50,486
Segment (operating) profit (loss)	8,091		392	8,483	0	8,483
Finance income						68
Finance expenses						(118)
Profit before tax						8,433

-12-

Filing Compare · SAWAI GROUP HOLDINGS Co., Ltd.